The relationship between psoriasis and increased risk of cardiovascular disease (CVD) is
controversial. We critically evaluate 14 cohorts and meta-analyze the magnitude of CVD risk …

… Petrof, J. Donnelly (British National Formulary), C. Saunders (British Dermatological
Nursing Group), AG Brain (BAD Scientific Administrator), LS Exton (BAD Information Scientist) …

A comprehensive evaluation of the risk of serious infections in biologic therapies for psoriasis
is lacking. We performed a systematic review and meta-analysis of randomized controlled …

For people without CVD, assess 10 year risk of a CVD event using QRISK3. This can be
done as part of NHS health checks and for people likely to be at high risk based on data …

This concise guideline summarises the key recommendations from the recent National
Institute for Health and Care Excellence (NICE) clinical guideline on the assessment and …

Background Biologic therapies have revolutionised the care of patients with psoriasis,
although they come at significant extra cost. Guidance on their use in the UK National Health …

… David Wonderling, 1 Alfredo Mariani, 1 Eleanor J Samarasekera, 1 Colin Wilkinson, 2
Riyaz S Patel, 3 , 4 Joseph Mills5, on behalf of the Guideline Committee … Members of the …

… Eleanor Samarasekera research fellow1, Laura Sawyer senior health … Rabar (until February
2011), Eleanor Samarasekera, Laura Sawyer, Natasha Smeaton, … J Invest Dermatol 2012; …

Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized
controlled trials makes choosing between them difficult for patients, clinicians, and …

Pancreatitis can severely reduce quality of life and may reduce life expectancy. 1 2 Acute
and chronic pancreatitis are characterised by inflammation of the pancreas, and table 1 …